GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aeterna Zentaris
Aeterna Zentaris is a biopharmaceutical company specializing in rare diseases. Its stock price reflects its long history of clinical development and transformation. The chart exemplifies the volatility inherent in smaller companies in this sector.
Share prices of companies in the market segment - Specialized pharma
Aeterna Zentaris is a biopharmaceutical company specializing in the development and commercialization of drugs for the diagnosis and treatment of rare diseases. We classify it as a "Specialty Pharma" company. The chart below shows how investors value companies in the orphan disease sector.
Broad Market Index - GURU.Markets
Aeterna Zentaris is a Canadian biopharmaceutical company specializing in the development and commercialization of drugs for the diagnosis and treatment of rare diseases. It is a component of the GURU.Markets index, representing the biotechnology sector. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
AEZS - Daily change in the company's share price Aeterna Zentaris
For Aeterna Zentaris Inc., a biopharmaceutical company, daily volatility reflects sensitivity to clinical trial data and the commercial success of its diagnostic tests. This metric is an important element of analysis.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnostics and therapeutics. This segment has its own unique dynamics, driven by developments. The chart below shows the volatility in this sector, allowing you to compare AEZS stock performance with other market players.
Daily change in the price of a broad market stock, index - GURU.Markets
Aeterna Zentaris is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aeterna Zentaris
For Aeterna Zentaris, year-over-year performance is a story about its diagnostic tests and therapeutic developments. Its 12-month market cap reflects both sales of its growth hormone deficiency test and, more importantly, progress in its vaccine and other drug development programs, which are its bets for the future.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company. Its complex structure and strategy make it a unique player. This chart shows how the market evaluates its ability to generate value from its assets and commercialize its niche products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aeterna Zentaris, a specialty pharmaceutical company, focuses on the diagnosis and treatment of rare diseases. Its year-over-year market capitalization dynamics demonstrate how success in niche areas can create value. The company is less dependent on general economic cycles, but is highly dependent on regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aeterna Zentaris
Aeterna Zentaris is a biopharmaceutical company. Its monthly performance depends on the progress of its clinical programs and its ability to secure licensing agreements. News of trial results or partnerships are the main drivers.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing drugs for the diagnosis and treatment of rare diseases. The chart below shows the overall dynamics of the specialty pharmaceutical sector, where the company occupies a niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aeterna Zentaris is a pharmaceutical company specializing in the diagnosis and treatment of rare diseases. Its performance depends on drug sales and progress in developing new ones. This makes it less volatile than biotech startups, but still susceptible to industry-specific events.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aeterna Zentaris
Shares of Aeterna Zentaris, a biopharmaceutical company, are news-sensitive. Weekly price movements depend on the results of clinical trials and the commercialization of its diagnostic and therapeutic products. The chart below shows how short-term scientific and regulatory developments affect the valuation of this niche player.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Aeterna Zentaris is a pharmaceutical company specializing in the diagnosis and treatment of rare diseases. Its narrow focus makes its shares sensitive to news related to its specific products. The chart below shows how its performance compares to that of diversified pharmaceutical giants.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aeterna Zentaris is a biopharmaceutical company. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by news about the progress of its drug candidates' clinical trials, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
AEZS - Market capitalization of the company Aeterna Zentaris
Aeterna Zentaris's price chart reflects its long history in biotechnology and its current focus on diagnosing and treating rare diseases. Its market cap reflects how investors view its new strategy and developments after years of research.
AEZS - Share of the company's market capitalization Aeterna Zentaris within the market segment - Specialized pharma
Aeterna Zentaris's market share in the pharmaceutical industry reflects its focus on rare diseases and diagnostic tests. Its market share is determined by the value of its commercialized products and research programs, making it a niche yet stable player in its field.
Market capitalization of the market segment - Specialized pharma
This chart shows the overall market capitalization of niche pharmaceutical companies. Aeterna Zentaris is an example of such a player, focusing on rare diseases and diagnostics. The dynamics on the chart reflect how the market values the company's development portfolio and commercial prospects.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of a biotech company focused on rare diseases. Aeterna Zentaris's market capitalization is a measure of its diagnostic and therapeutic developments. The line shows how a small, highly specialized company is fighting for its share of the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
AEZS - Book value capitalization of the company Aeterna Zentaris
Aeterna Zentaris's book value represents its scientific capital. The chart below reflects the valuation of its development pipeline in the fields of diagnostics and therapy for rare diseases and oncology. The pipeline's growth reflects success in clinical trials and partnerships, which are the company's core assets.
AEZS - Share of the company's book capitalization Aeterna Zentaris within the market segment - Specialized pharma
Aeterna Zentaris's tangible assets include its R&D infrastructure for developing and commercializing specialized pharmaceuticals. The chart shows its share of this scientific base, which forms the foundation for its therapeutic and diagnostic products.
Market segment balance sheet capitalization - Specialized pharma
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. Aeterna Zentaris, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Aeterna Zentaris is a specialty pharmaceutical company. Its assets include a portfolio of drugs in development and commercialized, as well as intellectual property. The chart below shows the company's financial weight in its therapeutic niche.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company. Its market capitalization reflects the value of its portfolio of currently marketed niche drugs and its ability to acquire and develop new products.
Market to book capitalization ratio in a market segment - Specialized pharma
Aeterna Zentaris Inc. is a pharmaceutical company specializing in the development of diagnostic and therapeutic drugs. Its value depends on the success of its products and developments. This chart shows how the market values its portfolio relative to its tangible assets.
Market to book capitalization ratio for the market as a whole
Aeterna Zentaris is a specialty pharmaceutical company. This chart shows how the market values their pipeline of development and commercialized products. The dynamics reflect progress in research and commercialization, as well as partnerships.
Debts of the company, segment and market as a whole
AEZS - Company debts Aeterna Zentaris
Aeterna Zentaris, a specialty pharmaceutical company, leverages its financial structure to develop and commercialize diagnostic tests and therapeutic drugs. This chart shows how the company invests in its clinical programs, aiming to bring new products to market in its niche areas.
Market segment debts - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnostics and therapeutics. This chart shows how its debt policy reflects its strategy for commercializing existing products and developing new ones, as well as how it manages its capital to finance its activities in niche segments of the pharmaceutical market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aeterna Zentaris
Affimed develops innovative cancer immunotherapy drugs. Its NK cell-engager technology requires significant investment in clinical trials. This chart illustrates the company's reliance on external funding, including debt, to advance its promising but high-risk platform.
Market segment debt to market segment book capitalization - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company developing and commercializing drugs in endocrinology and oncology. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how a small company finances its niche research.
Debt to book value of all companies in the market
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnostics and therapeutics. Its business model can encompass both proprietary drug development and commercialization. This chart of total market debt provides context for assessing how the company finances its niche products and clinical programs in the competitive pharmaceutical industry.
P/E of the company, segment and market as a whole
P/E - Aeterna Zentaris
For Aeterna Zentaris, a specialty pharmaceutical company, the P/E ratio is irrelevant. The company has no stable profitability. Its valuation on this chart is arbitrary. Its true value is determined by the potential of its scientific developments and investors' confidence in the success of clinical trials.
P/E of the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company developing and commercializing drugs in endocrinology and rare diseases. This chart shows the average valuation for the specialty pharmaceutical sector, reflecting how investors value companies with a narrow focus and niche products.
P/E of the market as a whole
Aeterna Zentaris is a specialty pharmaceutical company focused on developing and commercializing drugs for the diagnosis and treatment of rare diseases. The company has a long history in biotechnology. This risk appetite chart helps understand how investors value small specialty pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company focused on the development and commercialization of diagnostic and therapeutic drugs. This chart reflects analysts' expectations for future revenue, which are dependent on successful sales of existing products and progress in developing new ones.
%20P%2FE%20Aeterna%20Zentaris&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aeterna-Zentaris&v=1772630951727 "Chart of the company's future (projected) P/E Aeterna Zentaris")
Future (projected) P/E of the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on the diagnosis and treatment of rare diseases. This chart compares its future profitability expectations with those of the biopharmaceutical sector. It helps understand how the market perceives the commercial potential of its products and developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772630951758 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Aeterna Zentaris is a specialty pharmaceutical company focused on the diagnosis and treatment of rare diseases. Its success depends on the commercialization of existing products and R&D results. The overall market environment, visible in this chart, influences the availability of capital for biotech companies and the overall healthcare environment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772630951780 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company focused on the diagnosis and treatment of rare diseases. Its financial performance depends on sales of its commercial products and the success of developing new ones. This chart shows how the company balances revenue from existing products with investments in future growth.
Profit of companies in the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic drugs. This graph, showing overall sector profitability, reflects the complexity and diversity of the pharmaceutical market. Aeterna's success in bringing its niche products to market directly impacts its overall profitability.
Overall market profit
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnosing and treating rare diseases. Its business model often involves partnerships and product licensing. Success depends on its ability to identify and develop niche therapeutic solutions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aeterna Zentaris
Aeterna Zentaris is a specialized biopharmaceutical company. Its future revenue projections depend on the success of its diagnostic testing and therapeutic drug development. Analysts assess the commercial potential of its product portfolio and partnerships.
%20profit%20of%20the%20company%20Aeterna%20Zentaris&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aeterna-Zentaris&v=1772630951931 "Graph of future (projected) profit of the company Aeterna Zentaris")
Future (predicted) profit of companies in the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on developing drugs in endocrinology and oncology. This chart shows revenue forecasts for the entire pharmaceutical sector. It helps assess how the company's niche strategy and development pipeline compare to overall industry trends and competition.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772630952050 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Aeterna Zentaris is a specialty pharmaceutical company. Its success depends on the results of clinical trials and the commercialization of its products. This chart, reflecting overall market sentiment, is important. During periods of economic growth and stability, investors are more inclined to fund biotech companies, making it easier to raise capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772630952098 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company developing and commercializing drugs across various therapeutic areas. This chart, which correlates market capitalization with revenue, reflects an assessment of its current product portfolio and its ability to bring new drugs to market or find partners for them.
P/S market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on developing and commercializing drugs for the diagnosis and treatment of rare diseases and oncology. This chart reflects investor estimates of biotech revenue, helping to understand how the market perceives the commercial potential of Aeterna Zentaris' niche products and developments.
P/S of the market as a whole
Aeterna Zentaris is a specialty pharmaceutical company commercializing and developing drugs in various therapeutic areas, including oncology and endocrinology. This chart helps assess how the market perceives smaller pharmaceutical companies with a diversified portfolio.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnostics and therapeutics. This chart shows how the market values the company based on its projected future revenues from sales of existing products and potential new drugs. It reflects expectations for its commercial and R&D efforts.
%20P%2FS%20Aeterna%20Zentaris&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aeterna-Zentaris&v=1772630952354 "The graph of the company's future (projected) P/S Aeterna Zentaris")
Future (projected) P/S of the market segment - Specialized pharma
Aeterna Zentaris is a specialty biopharmaceutical company focused on commercialization and development of drugs in various therapeutic areas. This chart shows the average estimated future revenue in the specialty pharmaceuticals sector. It helps understand how investors view the company's current product portfolio and development strategy compared to its competitors.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772630952365 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Aeterna Zentaris (AEZS) is a specialty pharmaceutical company focused on diagnostics and treatment of rare diseases. Their success depends on sales of existing products and clinical trial results for new candidates. This chart does not reflect their potential in niche areas of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772630952431 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company. Its revenue comes from both sales of approved diagnostic tests and potential licensing agreements for its drug candidates. This chart reflects its hybrid model, combining commercial sales and long-term scientific development.
Sales of companies in the market segment - Specialized pharma
Aeterna Zentaris is a pharmaceutical company specializing in the diagnosis and treatment of rare diseases. Its revenue is generated through sales of the Macrilen diagnostic test. Its revenue structure may also include payments from partnerships for the development of new therapeutic drugs.
Overall market sales
Aeterna Zentaris Inc. is a specialty pharmaceutical company focused on diagnostics and therapeutics. Its success depends on the commercialization of its products and research results. The overall economic situation, shown in this chart, influences healthcare budgets and the investment climate in the pharmaceutical sector, which is important for the development and launch of new products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company that develops and commercializes diagnostic tests and therapeutic drugs. This chart shows analyst expectations for its product sales and research progress.
%20sales%20of%20the%20company%20Aeterna%20Zentaris&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aeterna-Zentaris&v=1772630952528 "Schedule of future (projected) sales of the company Aeterna Zentaris")
Future (projected) sales of companies in the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company that develops and commercializes drugs for the diagnosis and treatment of rare diseases. This chart shows the outlook for the specialty pharmaceutical industry. It reflects the high interest in orphan drugs, which often receive regulatory exemptions and command high prices.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772630952561 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important for Aeterna Zentaris. The pharmaceutical company relies on funding for its research and development. Capital inflows into the industry increase during periods of overall economic confidence and investor risk appetite.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772630952592 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnosing and treating rare diseases. This chart illustrates the profitability of its niche strategy. Profitability depends on sales of its commercial products and success in developing new therapeutics for small patient populations.
Market segment marginality - Specialized pharma
Aeterna Zentaris is a biopharmaceutical company specializing in the development of drugs for rare diseases and endocrinology. Profitability depends on the success of its clinical developments. This chart shows the average profitability in the pharmaceutical industry, helping to assess the potential of its niche pharmaceutical products.
Market marginality as a whole
Aeterna Zentaris is a specialty pharmaceutical company that develops and commercializes diagnostic tests and therapeutic drugs. Its success depends on demand from the medical community and healthcare systems. This demand, reflecting the overall economic situation, impacts hospital budgets and their ability to implement new diagnostic solutions.
Employees in the company, segment and market as a whole
Number of employees in the company Aeterna Zentaris
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnosing and treating rare diseases. This chart reflects its compact team dedicated to research and commercialization. The dynamics illustrate how the company manages the lifecycle of its products and advances new candidates through the regulatory process.
Share of the company's employees Aeterna Zentaris within the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on the development and commercialization of drugs in endocrinology and oncology. This chart shows the company's share of the total number of specialists in its narrow therapeutic areas. This reflects its research portfolio and commercial efforts.
Number of employees in the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company developing and commercializing drugs for the diagnosis and treatment of rare diseases. This chart, which reflects employment in the pharmaceutical industry, provides a general overview. The growing number of specialists focused on orphan diseases indicates the growing attractiveness of this market segment.
Number of employees in the market as a whole
Aeterna Zentaris is a pharmaceutical company specializing in rare diseases. This overall occupancy chart reflects the healthcare system's ability to pay for expensive treatments. The stable economy shown here ensures a steady flow of insurance premiums, which allows for the coverage of innovative drugs for specific patient groups.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aeterna Zentaris (AEZS)
Aeterna Zentaris (AEZS) is a specialty pharmaceutical company focused on diagnostics and therapeutics. This chart shows the valuation of their "intellectual capital." Whether it's a diagnostic test or a therapeutic drug, a company's market value is determined by its patents and regulatory approvals, not the size of its workforce.
%20of%20the%20company%20Aeterna%20Zentaris%20(AEZS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aeterna-Zentaris-AEZS&v=1772630952738 "Chart of market capitalization per employee (in thousands of dollars) of the company Aeterna Zentaris (AEZS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company. Its business model can encompass both the development of its own drugs and the commercialization of those already approved. This chart allows us to assess how effectively the company manages its portfolio and personnel to create market value compared to other players in the pharmaceutical industry.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772630952752 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Aeterna Zentaris is a specialty pharmaceutical company focused on diagnostics and therapeutics. Its business model can encompass both proprietary drug development and commercialization. This chart shows how the market views its portfolio and the ability of its small team to successfully bring niche products to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772630952769 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aeterna Zentaris (AEZS)
Aeterna Zentaris is a specialty pharmaceutical company. They focus less on R&D and more on commercializing niche diagnostic tests and therapeutic drugs. This chart shows how successfully their small commercial team generates revenue from sales of these specialized products.
%20Chart%20Aeterna%20Zentaris%20(AEZS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aeterna-Zentaris-AEZS&v=1772630952781 "Company Profit Per Employee (in thousands of dollars) Chart Aeterna Zentaris (AEZS)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company focused on the development and commercialization of drugs in endocrinology and oncology. This chart reflects the effectiveness of its business model, which can include both in-house development and licensing. Success depends on demand for its niche products and the effectiveness of its commercial team.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772630952786 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Aeterna Zentaris (AEZS) is a biopharmaceutical company specializing in the development and commercialization of diagnostic tests (e.g., a test for growth hormone deficiency). This is a niche segment of the pharmaceutical industry. This indicator shows how a biotech company with a commercial product (not just R&D) generates revenue from its scientific and commercial staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772630952806 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aeterna Zentaris (AEZS)
Aeterna Zentaris is a specialty pharmaceutical company. This chart shows how the company is commercializing its products and diagnostic tests. Revenue per employee growth will depend on the success of their commercial products and the results of clinical trials of new drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aeterna-Zentaris-AEZS&v=1772630952874 "Sales chart per company employee Aeterna Zentaris (AEZS)")
Sales per employee in the market segment - Specialized pharma
Aeterna Zentaris is a pharmaceutical company that has shifted its focus from R&D to commercialization, specifically the promotion of drugs (for example, for diagnosing growth hormone deficiency). This chart shows how productive their commercial team is, reflecting their ability to generate sales revenue and royalties.
Sales per employee for the market as a whole
Dorchester Minerals (DMLP) is a partnership that doesn't drill or mine. They own the land rights and royalties for oil and gas production on that land. Operators (other companies) produce and pay DMLP a percentage (royalty). This chart is an example of the royalty model. DMLP has a minimal staff managing these assets. This allows them to generate significant per-employee income, which fluctuates with oil and gas prices.
Short shares by company, segment and market as a whole
Shares shorted by company Aeterna Zentaris (AEZS)
Aeterna Zentaris (AEZS) is another biotech company with a long history of development and failure. This chart tracks bearish bets. The shorts reflect the market's belief that the company, having burned through cash for decades, will never be able to bring a product to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aeterna-Zentaris-AEZS&v=1772630952946 "Short Shares Chart for the Company Aeterna Zentaris (AEZS)")
Shares shorted by market segment - Specialized pharma
Aeterna Zentaris (AEZS) is a specialty pharmaceutical company that develops and commercializes diagnostic tests and therapeutic drugs. The chart below represents a general short position in the biotech sector, demonstrating the general investor skepticism regarding the success of its developments.
Shares shorted by the overall market
Aeterna Zentaris (AEZS) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aeterna Zentaris (AEZS)
This chart for Aeterna Zentaris is a barometer of biotech speculation. The company has a long history of endocrinology development, often with mergers and acquisitions and shifts in focus. "Overheated" (above 70) occurs with announcements of new clinical programs. A lack of commercial success and a constant need for capital lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aeterna-Zentaris-AEZS&v=1772630952974 "RSI 14 indicator chart for the company's stock Aeterna Zentaris (AEZS)")
RSI 14 Market Segment - Specialized pharma
Aeterna Zentaris is a biotech (Canada), a "hormone hunter." Their focus is endocrinology (diagnostics, therapy). The "Specialized Pharma" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is AEZS's growth due to their R&D, or is the entire biotech sector "overheated?"
RSI 14 for the overall market
Aeterna Zentaris (AEZS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AEZS (Aeterna Zentaris)
Aeterna Zentaris (AEZS) is a biopharmaceutical company specializing in the diagnosis and treatment of rare endocrine diseases. This chart shows the average 12-month forecast, reflecting analyst expectations for the company's diagnostic test sales and development potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AEZS-Aeterna-Zentaris&v=1772630953006 "A chart showing analyst consensus forecasts for the expected stock price. AEZS (Aeterna Zentaris)")
The difference between the consensus estimate and the actual stock price AEZS (Aeterna Zentaris)
Aeterna Zentaris (AEZS) is a biotech company specializing in developing drugs to treat rare endocrine diseases. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AEZS-Aeterna-Zentaris&v=1772630953042 "A chart showing the difference between the consensus forecast and the actual stock price. AEZS (Aeterna Zentaris)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Aeterna Zentaris is a biotech company specializing in rare endocrine diseases and diagnostic tests. This chart shows general expectations for the specialty pharmaceutical sector, reflecting whether experts believe R&D investments in this niche will be successful.
Analysts' consensus forecast for the overall market share price
Aeterna Zentaris (AEZS) is a biopharmaceutical company focused on the development and commercialization of niche drugs, including diagnostics. This chart shows the overall risk appetite in the market. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aeterna Zentaris
Aeterna Zentaris is a biotech R&D company focused on diagnostics. Their only commercial product (Macrilen) is a diagnostic test for growth hormone deficiency in adults. This chart summarizes their commercialization history. It reflects their (very slow) sales growth of this ultra-niche test and their R&D efforts to expand its use.
AKIMA Market Segment Index - Specialized pharma
Aeterna Zentaris is a specialty pharmaceutical company. They often focus on niche drugs, endocrinology diagnostic tests, and repositioning older medications. This chart compares their composite index to their sector, showing how their specialized strategy outperforms their competitors.
The AKIM Index for the overall market
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing drugs (diagnosing growth hormone deficiency). This chart, reflecting the market average, provides a macro backdrop. It helps assess how AEZS, which is optimizing its portfolio, compares to overall economic trends.
